RegCell Hires Michael McCullar as CEO

Published on: 

Company’s new leader previously served in the same role at OnQuality Pharmaceuticals.

RegCell, a biotech company, revealed that it has officially appointed Michael McCullar as CEO and representative director. Previously, he served as CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities.


"I am honored to join this remarkable team at an exciting time for RegCell as we prepare to enter the clinical stage and to support the company's mission to discover innovative treatments for autoimmune diseases," said McCullar. "In an era where the increasingly aging population is facing an escalating burden of autoimmune disorders, Treg-based cellular therapies are opening the doors to exciting new treatment possibilities. I look forward to contributing my expertise towards validating the promising potential of our regulatory T cell platform and expanding our U.S. footprint as we advance our programs towards the clinic in 2024."

Reference: RegCell Appoints Experienced Life Science Executive and Entrepreneur Michael McCullar, Ph.D., MBA, as its New Chief Executive Officer. PR Newswire. October 19, 2023. Accessed October 19, 2023.